GlassScriptPhysician profile
John M Stafford
NPI 1730182247
$5,626.60
in general payments reported to CMS, 2019-2025
32 companies · $762 in 2025
The $762 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,117 · 2020: $320 · 2021: $460 · 2022: $1,299 · 2023: $958 · 2024: $711 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,430.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $772.04 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $543.37 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $497.60 | 2019-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $424.43 | 2020-2025 | Jardiance, Mounjaro, Emgality |
| Astrazeneca Pharmaceuticals LP | $368.69 | 2019-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $332.18 | 2019-2025 | Jardiance, Tradjenta, Stiolto Respimat |
| Merck Sharp & Dohme LLC | $329.23 | 2019-2024 | Vaxneuvance, Capvaxive, Pneumovax 23 |
| Pfizer INC. | $288.64 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $240.55 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $195.84 | 2022-2025 | Caplyta |
| Astellas Pharma US INC | $194.35 | 2019-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $172.98 | 2022-2023 | Proclaim |
| Daiichi Sankyo INC. | $157.89 | 2019-2024 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $147.44 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $139.46 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $129.76 | 2022-2024 | |
| Exact Sciences Corporation | $127.77 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $68.58 | 2019-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $65.57 | 2019-2020 | |
| Almatica Pharma LLC | $50.35 | 2021-2023 | Loreev Xr, Gralise |
| Biohaven Pharmaceuticals, INC. | $47.12 | 2021 | |
| Supernus Pharmaceuticals, INC. | $44.88 | 2022-2023 | Qelbree |
| Actelion Pharmaceuticals US, INC. | $38.31 | 2022 | |
| Shire North American Group INC | $36.21 | 2019 | |
| Amarin Pharma, INC. | $33.30 | 2021 | |
| Allergan, INC. | $29.99 | 2020 | |
| Amgen INC. | $29.24 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $27.66 | 2025 | Zoryve |
| Axsome Therapeutics, INC. | $25.77 | 2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $24.95 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $23.23 | 2023 | Jornay Pm |
| Biohaven Pharmaceutical Holding Company LTD. | $19.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Stafford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.